The Effect of Obesity and Weight Loss in Heart Failure With Reduced Ejection Fraction.
Launched by UNIVERSITY OF OXFORD · Jul 3, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how losing weight can help people who have heart failure with reduced ejection fraction (HFpEF) and are overweight or obese. The main goals are to see if weight loss can improve the shape of the heart and how well it pumps blood, as well as enhance the person's quality of life and ability to exercise. Participants will take part in two visits spaced out by 3 to 6 months. During this time, they will either join a weight loss program or continue with their usual care.
To be eligible for this study, participants should be between the ages of 65 and 74, have heart failure defined by a specific heart function measurement, and have a body mass index (BMI) greater than 27.5. Those who join the weight loss group will follow a special diet that includes meal replacement products for 8 weeks, followed by a guided plan to gradually reintroduce regular foods. Throughout the trial, participants will undergo various assessments, including questionnaires, body measurements, blood tests, and heart scans, to monitor their progress and overall health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Heart failure determined by left ventricular ejection fraction 20-45%
- • Body mass index \> 27.5kg/m\^2
- Exclusion Criteria:
- • Contraindications to magnetic resonance imaging
- • NYHA class IV
- • Pregnancy, planned pregnancy or lactating
- • Significant valvular, ischemic, infiltrative or other potentially confounding cardiac disease
- • Any other conditions which may potentially compromise the safety or scientific validity of the study
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, , United Kingdom
Jersey, , Jersey
Patients applied
Trial Officials
Oliver J Rider, DPhil
Principal Investigator
University of Oxford
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported